Immune Response to Respiratory Syncytial Virus (RSV) in Health Care Workers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01563692|
Recruitment Status : Completed
First Posted : March 27, 2012
Last Update Posted : November 9, 2015
Respiratory Syncytial Virus (RSV) is a human restricted pathogen and is the single most important cause of severe respiratory illness in infants and young children, a major cause of infantile bronchiolitis and is the most frequent cause of hospitalization of infants and young children in industrialized countries. Severe RSV infection early in life is associated with an increased risk of subsequent recurrent wheezing and asthma. There are few population-based estimates of the incidence of RSV disease from developing countries, but the existing data clearly indicates that the virus accounts for a high proportion of Acute Respiratory Infections (ARI) in children. Studies in Brazil, Colombia and Thailand suggest that RSV causes 20-30% of ARI cases in children from 1-4 years of age, a proportion similar to that in industrialized countries, and WHO has estimated the global RSV disease burden at 64 million cases and 160 000 deaths every year. RSV also causes severe disease in elderly and immune-compromised adults, and the burden of RSV disease in the elderly is comparable to that of seasonal influenza. The economic impact of RSV-related disease in adults estimated to be greater than that of influenza in relation to numbers of days lost from work.
The development of a safe and effective vaccine against RSV would benefit greatly from data on the immune responses in healthy adults naturally exposed to the virus. RSV infection has been shown to increase and induce short-lived circulating antibody secreting cells and produce an increase in the RSV specific antibody titres but very limited data is available on the cellular immune responses induced by RSV during natural infection in healthy adults. The existence of cell mediated immune response against RSV in humans has been described but characterization of this response remains poor and simultaneous analysis of several immunological parameters have not been attempted in an RSV exposed population before.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Infection in Health Care Personnel|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||August 2012|
Paediatric health care workers
NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
Non-paediatric health care workers
This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
- Immune response to natural RSV exposure [ Time Frame: July 2012 (up to 4 months) ]To assess the induction of cellular responses and antibodies following natural exposure to RSV
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563692
|Centre for Clinical Vaccinology and Tropical Medicine|
|Oxford, United Kingdom, OX3 7LE|
|Principal Investigator:||Andrew J Pollard, PhD||University of Oxford|